Navigation Links
DFH Pharma, USA Partners with Hetero Group, INDIA to Develop 2nd Generation HIV Maturation Inhibitor Drugs
Date:4/3/2013

GAITHERSBURG, Md., April 3, 2013 /PRNewswire-iReach/ -- DFH Pharma, Inc. ("DFH"), a privately held pharmaceutical company focused on the development of HIV therapeutics, announced that it has entered into a Research and Product Development Agreement with Hetero Group ("HETERO"), a privately held research-based global pharmaceutical group with headquarters in Hyderabad, Andhra Pradesh, India, to develop the next generation of HIV maturation inhibitor drugs.

Maturation inhibitors are a new class of HIV drug that blocks virus replication by interfering with the formation of infectious HIV virus.  The clinical proof-of-concept for maturation inhibitors was established in HIV-infected patients with the first-in-class drug bevirimat. While bevirimat was shown to be safe, well-tolerated and effective in reducing virus in many patients, only limited effectiveness was observed in others.  It was determined that this variable response to bevirimat was due to small changes in the makeup of a key viral structural protein in different HIV strains.  The goal of the current effort is to identify maturation inhibitor drugs that are effective against all HIV strains, including those with the types of changes associated with reduced sensitivity to bevirimat.

The focus of the joint R&D effort is to expedite research into and the development of new maturation inhibitor drugs by combining DFH Pharma's background and experience in HIV therapeutic development with Hetero's world class expertise in product development, medicinal chemistry, manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms.  "We are very excited to be working with Hetero, to develop the next generation of HIV maturation inhibitor drugs," said Dr. Carl Wild , DFH Pharma President & CEO. "The partnership will provide DFH access to Hetero's world-class chemistry and product development capabilities allowing for the rapid return of maturation inhibitor drug candidates to the clinic." DFH Pharma provided an update on progress to identify new maturation inhibitor drugs in a presentation to the 20th annual Conference on Retroviruses and Opportunistic Infections held recently in Atlanta, GA.

Dr. B.P.S. Reddy , Founder, Chairman & Managing Director of Hetero said "The collaboration with DFH will give a new paradigm to our discovery program(s). The DFH team's clinical expertise with HIV drugs will complement our drug discovery capabilities to expedite the development and enhance the success rate". He also stated that "This collaboration strengthens our commitment towards our work in the HIV therapeutic area."

About Maturation Inhibitors
Maturation inhibitors are a new class of antiretroviral drug candidates that inhibit HIV-1 replication by interfering with virus maturation. Specifically, drugs in this class block the last step in the processing of the HIV-1 Gag protein. This interference leads to the formation of noninfectious, immature virus particles, thus preventing subsequent rounds of HIV infection. As expected for a novel mechanism of action, these drugs retain inhibitory activity against HIV isolates resistant to all classes of currently approved drugs commonly used by HIV infected patients. The DFH-Hetero Team plans to develop maturation inhibitors for application in both first-line and salvage therapy.

About DFH Pharma, Inc.
DFH Pharma was founded by Carl Wild , PhD and David E. Martin , PharmD in 2011. Dr. Wild is a co-founder of Panacos Pharmaceuticals and served as Chief Science Officer. He serves as DFH's President and Chief Executive Officer as well as on the Board of Directors.  While at Duke University, Dr. Wild discovered the Fusion Inhibitor class of HIV drugs and invented the first approved member of that drug class, Fuzeon® (Enfuvirtide). Dr. Martin was Senior Vice President, Drug Development and Regulatory Affairs at Panacos.  He serves as DFH's Chief Development Officer and on the Board of Directors.  While at Panacos, Drs. Wild and Martin played critical roles in the development of bevirimat, the first-in-class maturation inhibitor drug. In addition, Dr. T.J. Nitz serves as Chief Science Officer. Dr. Nitz was Senior Director of Chemistry at Panacos and headed up the medicinal chemistry program that resulted in the discovery of the second-generation maturation inhibitors. Together, the DFH Pharma team has more than 60 years of experience in antiviral drug discovery and development.

About Hetero Group
Hetero Group, headquartered at Hyderabad, India, is a research driven vertically integrated pharmaceutical company and manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, and ANVISA Brazil. The company's robust product portfolio is spread over all therapeutic/product areas with emphasis in Anti-Retrovirals and Oncology and are supported by an outstanding R&D set-up. The company is marketing these products globally and has operations in India, USA, Europe, Latin America, Middle East, Africa and other emerging markets. Hetero has approximately 25% of the global Anti-Retroviral market segment and works with various prominent agencies such as Clinton Health Initiative, PEPFAR, MSF, UNICEF, VPP, and USAID to provide cost effective medicines to the under developed and developing countries.

Media Contact: David Martin DFH Pharma, Inc., 301-538-1878, dmartin@dfhpharma.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE DFH Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
2. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
3. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.
4. InnoPharma, Inc., Announces U.S. FDA Approval of Acetylcysteine Solution, USP, 20% for Inhalation or Oral Administration
5. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
7. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
8. ACTEON North America Partners with Marketing and PR Firm Verasoni Worldwide
9. New Autism Detection System Commercialized through Partnership of IP Shakti, LLC and Shizuoka University
10. RoundTable Healthcare Partners and Argon Medical Devices to Acquire Angiotech Pharmaceuticals Interventional Products Business
11. SciGene and BioDot Ink Partnership for Automated FISH Slide Processor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Henry Schein, Inc. (Nasdaq: ... care products and services to office-based dental, animal health and ... equity investment in Marrodent, one of Poland,s ... $32 million. This transaction was announced on August 30, 2016. ... Poland since 2014, and Marrodent marks ...
(Date:12/8/2016)... 2016 Research and Markets has announced the addition ... to their offering. ... The report provides separate comprehensive analytics for ... and Rest of World. Annual estimates and forecasts are ... is provided for these markets. Market data and analytics are derived from ...
(Date:12/7/2016)... -- "Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight" report by ... drug in clinical pipeline. Currently 5 biosimilar version of Lantus are commercially ... Kenya , Czech Republic , ... , Slovakia , United Kingdom ... patent on Lantus expired in 2014. Lantus is the brand name ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and ... the ultimate weight loss and wellness program, at their world headquarters of Omni La ... immediate and long-term results to anyone seeking weight loss, personal development, a healthy lifestyle, ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... continuity to its innovative Unified Instance Manager architecture, meeting the needs of ... new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, provides ...
(Date:12/8/2016)... ... 08, 2016 , ... STATEN ISLAND, N.Y., Nov. 24, 2016 ... the highest standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) ... Dr. Daniel Messina. , Among the recognitions, the American College of Surgeons' (ACS) ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, signed into law ... in 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition ... to the study, medical payments per claim in California decreased 4 percent in 2013 ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Care Act. Dr. Botelho advocates for the mass media launching of story movements ... ongoing opportunities to share their unfortunate experiences; such a movement can generate the ...
Breaking Medicine News(10 mins):